GlobeNewswire by notified

360 Law Group selects Kim as its Document Automation Platform and Agrees Go-To-Market Alliance

Share

LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- 360 Business Law (www.360businesslaw.com) and its England & Wales SRA Regulated sister company 360 Law Services (www.360lawservices.com), both technology-led law firms with over 500 lawyers operating in over 100 jurisdictions, has selected Kim Document as its document automation platform for use cases spanning instruction intake through first draft contract generation to government forms and filings.

The practices act for a wide range of clients across multiple industry sectors, from start-ups and mid-market companies to global public and private household name companies, FTSE 250 listed organizations in the UK, and NASDAQ quoted companies in the US.

Commenting on the partnership, Robert Taylor, CEO of 360 Law Group said, “We are always looking for ways to deliver better client value, increase efficiency and streamline our operations across the 100 jurisdictions in which we operate. When we first saw Kim, we thought that it was too good to be true: a great combination of globally scalable functionality that is easy to use and deploy at affordable business software prices. We are excited to not only use Kim but also to showcase and take it to our clients who we also believe will benefit significantly from adopting it.”

Karl Chapman, CEO of Kim Technologies said, “When we first met the 360 Law Group team, it was quite surreal. The firm has many of the characteristics of Riverview Law, which we set up in 2012 and which was subsequently acquired by EY. After the first hour, it was clear that not only do we speak the same language, but that Robert and his team are totally client-focused and understand that all roads lead to effective intake management and work allocation supported by document automation and actionable data – all of which Kim excels at. We look forward to working with the 360 Law Group team and its clients.”

Kim (www.kimdocument.com) is a no-code, SaaS, patent-protected document generation, assembly, and workflow automation platform. Kim assists knowledge workers around the globe in automating and generating documents, capturing data and using that data to generate other documents or populate other systems. The solution is available from a browser, MS Teams and other systems and is quick to implement, making it a valuable tool for businesses looking to start or supercharge their digitization, data capture and document automation programs.

For further information, please contact Becky Roberts: rebecca.roberts@kimtechnologies.com

About 360 Law Group

Strip away the overheads of traditional law firms, including prime office locations, add a sprinkle of cloud-based technology, and the result is 360 Business Law™ and 360 Law Services™. With over 500 lawyers operating in over 100 jurisdictions, our practices act for a wide range of clients across multiple industry sectors, from start-ups, mid-market companies, through to global public and private household name companies, FTSE 250 listed organizations in the UK and NASDAQ quoted companies in the US.

Our practices provide in-depth legal advisory to clients at exceptionally low hourly rates, fixed fees and via award-winning subscription packages.

For more information, please contact Robert Taylor r.taylor@360laswgroup.co.uk or visit www.360businesslaw.com or www.360lawservices.com. You can also follow us on LinkedIn, X (formally Twitter), Facebook, and Instagram.

About Kim

Kim is a no-code, SaaS, patent-protected document generation, assembly and workflow automation tool. Kim’s Enterprise solution is proven with Fortune 500 organizations in legal, compliance, contract management, company secretarial, office productivity and other functions.

Kim’s Business tier allows any function or role in small, medium or large organizations to take their existing Word documents and automate them plus turn them into web applications that can be shared internally and/or externally. It automates letters, forms, records, checklists and contracts in minutes, with no training, integrates seamlessly with MS Teams, and is accessible from any browser.

Kim has two patents. When a DOCX template is uploaded into the Kim software it gains additional knowledge by learning the structural composition of each template and it can interface with any authenticated and authorized client over HTTPS with an intelligent understanding of the correctness of the data being supplied. This enables the automatic extraction of tags from the multiple sample documents, the storing of the tags in a data schema separate from the documents, automatically generating structural schemes from the tags, automatically creating document templates from the sample documents and processing the document templates to create unique identifiers (see ‘Patent Headlines’ section and the Kim patent: https://patents.justia.com/patent/10817662.

For more information visit www.kimdocument.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye